Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer

Apr 29, 2009

Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum.

Compared to placebo, sipuleucel-T extended median survival by 4.1 months and improved three-year survival by 38 percent. Sipuleucel-T successfully exceeded the pre-specified level of statistical significance defined by the study's design and reduced the overall risk of death by 22.5 percent compared to placebo (p-value=0.032). More than 500 patients were enrolled in the IMPACT trial, a multi-center, randomized, double-blind, placebo-controlled study evaluating men with asymptomatic or minimally symptomatic, metastatic, androgen-independent . The primary endpoint was overall survival.

Researchers are encouraged by the findings, citing an impressive effect on long-term survival for patients, compared to placebo.

"The ability to boost survival for patients is the gold standard endpoint in prostate cancer clinical trials," said AUA spokesperson Ira D. Sharlip, MD. "The ability to give these both increased survival and possibly, improved quality of life, is very important."

Sipuleucel-T is an investigational therapy for men with androgen-independent prostate cancer. It is an active cellular immunotherapy designed to use live to boost a patient's to elicit a long-lasting response against cancer.

Source: American Urological Association

Explore further: PDE-5 inhibitors tied to prostate cancer biochemical recurrence

add to favorites email to friend print save as pdf

Related Stories

Prostate cancer vaccines more effective with hormone therapy

Jul 10, 2008

Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, ...

Recommended for you

Cancer fear can impact screening uptake

12 hours ago

People who worry about cancer are more likely to want to get screened for colon cancer, but feeling uncomfortable at the thought of cancer makes them less likely to actually go for the test, finds new UCL-led ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.